PMID- 34989473
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20220716
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 15
IP  - 4
DP  - 2022 Apr
TI  - Polypharmacy influences the renal composite outcome in patients treated with 
      sodium-glucose cotransporter 2 inhibitors.
PG  - 1050-1062
LID - 10.1111/cts.13222 [doi]
AB  - Polypharmacy is a serious concern in general practice, especially among elder 
      patients; however, the evidence showing significantly poor renal outcomes is not 
      sufficient. This survey was performed to evaluate the effect of polypharmacy on 
      the incidence of the renal composite outcome among a sample of patients with 
      sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment. We assessed 624 
      Japanese patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease 
      who received SGLT2i treatment for greater than 1 year. The patients were 
      classified as those with concomitant treatment, that was limited to the 
      medications for hypertension, T2DM, and dyslipidemia, with greater than or equal 
      to seven medications (n = 110) and those with less than seven medications 
      (n = 514). Evaluation of the renal composite outcome was performed by propensity 
      score matching and stratification into quintiles. A subgroup analysis of patients 
      of greater than or equal to 62 years of age and less than 62 years of age was 
      also performed. The incidence of the renal composite outcome was larger in 
      patients with greater than or equal to seven medications than in those with less 
      than seven medications in the propensity score-matched cohort model (6% vs. 17%, 
      respectively, p = 0.007) and also in the quintile-stratified analysis (odds ratio 
      [OR], 2.23, 95% confidence interval [CI, 1.21-4.12, p = 0.01). The 
      quintile-stratified analysis of patients of less than 62 years of age-but not 
      those of greater than or equal to 62 years of age-also showed a significant 
      difference (OR, 3.29, 95% CI, 1.41-7.69, p = 0.006). Polypharmacy appears to be 
      associated to the incidence of the renal composite outcome, especially in young 
      patients.
CI  - (c) 2022 The Authors. Clinical and Translational Science published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Kobayashi, Kazuo
AU  - Kobayashi K
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
AD  - Department of Medical Science and Cardiorenal Medicine, Yokohama City University 
      Graduate School of Medicine, Yokohama, Japan.
FAU - Toyoda, Masao
AU  - Toyoda M
AD  - Division of Nephrology, Endocrinology and Metabolism, Department of internal 
      medicine, Tokai University School of Medicine, lsehara, Japan.
FAU - Hatori, Nobuo
AU  - Hatori N
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
FAU - Furuki, Takayuki
AU  - Furuki T
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
FAU - Sakai, Hiroyuki
AU  - Sakai H
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
FAU - Hatori, Yutaka
AU  - Hatori Y
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
FAU - Sato, Kazuyoshi
AU  - Sato K
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
FAU - Miyakawa, Masaaki
AU  - Miyakawa M
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
FAU - Tamura, Kouichi
AU  - Tamura K
AD  - Department of Medical Science and Cardiorenal Medicine, Yokohama City University 
      Graduate School of Medicine, Yokohama, Japan.
FAU - Kanamori, Akira
AU  - Kanamori A
AD  - Committee of Hypertension and Kidney disease, Kanagawa Physicians Association, 
      Yokohama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220112
PL  - United States
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 9NEZ333N27 (Sodium)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Female
MH  - Glucose/therapeutic use
MH  - Humans
MH  - Male
MH  - Polypharmacy
MH  - Sodium/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
PMC - PMC9010256
COIS- The authors declared no competing interests for this work.
EDAT- 2022/01/07 06:00
MHDA- 2022/04/19 06:00
PMCR- 2022/04/01
CRDT- 2022/01/06 08:55
PHST- 2021/12/15 00:00 [revised]
PHST- 2021/06/24 00:00 [received]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/01/07 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
PHST- 2022/01/06 08:55 [entrez]
PHST- 2022/04/01 00:00 [pmc-release]
AID - CTS13222 [pii]
AID - 10.1111/cts.13222 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2022 Apr;15(4):1050-1062. doi: 10.1111/cts.13222. Epub 2022 Jan 
      12.